Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 24 ASA I-II~* patients (age 18-60 years~* weight 50-89 kg~Exclusion Criteria:~* a known allergy to the study drugs~* significant cardiac~* respiratory, renal or hepatic diseases~* bleeding diathesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: ACTIVE_COMPARATOR): patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
- bupivacaine group (Type: PLACEBO_COMPARATOR): patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).